A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER"
Published:
January 31, 2023
by U.S. Fed News
|
AstraZeneca and Daiichi Sankyo’s Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer; in Europe, about 531,000 breast cancer patients are diagnosed annually with around 141,000 deaths
Published:
January 26, 2023
by AstraZeneca AB
|
Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based CDx test; test to identify patients with non-small cell lung cancer who may be eligible for treatment with Tagrisso osimertinib
Published:
January 25, 2023
by Clinical Lab Products
|
Pieris Pharmaceuticals GmbH and AstraZeneca Submit United States Patent Application for Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 and/or IL-13 to Their Respective Receptors
Published:
January 25, 2023
by Pharmaceutical Patent News
|
AstraZeneca Listed a New Clinical Trial to Study Safety, Tolerability, and Pharmacokinetics of AZD0186
Published:
January 24, 2023
by Contify Life Science News
|
Ask us about our Tissue & Hygiene market view
Trending Chart
Interactive chart with headline count